Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma

Allergy. 2021 Jun;76(6):1890-1893. doi: 10.1111/all.14693. Epub 2020 Dec 23.

Authors

Joanne E Kavanagh^{1

2}, Andrew P Hearn^{1

2}, Grainne d'Ancona¹, Jaideep Dhariwal¹, Cris Roxas¹, Linda Green¹, Louise Thomson¹, Mariana Fernandes¹, Brian D Kent^{3

4}, Alexandra M Nanzer¹, David J Jackson^{1

2}

Affiliations

¹ Guy's Severe Asthma Centre, Guy's Hospital, Guy's & St Thomas' NHS Trust, London, UK.
² School of Immunology & Microbial Sciences, King's College London, London, UK.
³ Department of Respiratory Medicine, St James' Hospital, Dublin, Ireland.
⁴ School of Medicine, Trinity College Dublin, Dublin, Ireland.

PMID: 33300186
DOI: 10.1111/all.14693

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Humans

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
benralizumab
mepolizumab